Allergan changes IOL manufacturing process to address lens yellowing problem.
This article was originally published in The Gray Sheet
Executive Summary
ALLERGAN IOL MANUFACTURING CHANGES MADE TO PREVENT LENS YELLOWING, a problem that led to a voluntary recall of the devices. AMO PhacoFlex II Model SI-30NB intraocular lenses, manufactured between July 13, 1995 and Oct. 31, 1995, "have a somewhat yellow appearance" that was caused by the packaging material used to ensure sterility during that time period, the firm explains in a Feb. 5 voluntary recall notice. An investigation by the firm "led to manufacturing changes to prevent this phenomenon from recurring," the firm states.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.